Regenerative Medicine
Repairing or replacing damaged tissue and organs rather than managing their decline.
Maturity
capability 4 / 5
deployment 2 / 5 ← sets the score
absorption 3 / 5
Bound by capital · trend improving.
Basis, source, vintage
Approved products exist and are deployed for narrow indications; commercial viability, not science, is the binding constraint, and complex organ regeneration remains preclinical.
Source: EMA CAT quarterly highlights (EMA/147429/2026): 31 ATMPs authorised Dec 2008–Dec 2025, 7 withdrawn and 2 expired. Peer-reviewed: Int. J. Technology Assessment in Health Care (2024) — 22% of EMA-authorised ATMPs withdrawn, six of seven for COMMERCIAL reasons, not safety or efficacy. FDA lists 40+ approved cell and gene therapy products. ⚠ No bioprinted or lab-grown SOLID organ has been implanted in a human with an established outcome (2008–2026)
Where you have already met this: Glybera was the first gene therapy approved in Europe. It worked. It cost about €1m per patient and recorded one sale before being withdrawn. Six of the seven European advanced-therapy withdrawals to date were for commercial reasons, not safety or efficacy.
If this moved: The absorption dimension is the one to watch, not capability. If reimbursement pathways existed for one-time high-cost interventions, approved therapies would reach patients who currently cannot get them. The science is not what is holding this back.
What to watch for: Payment models for a cure delivered once — outcome-based agreements, annuity payments. And manufacturing cost per patient, since autologous therapies are made individually.
Not to be confused with: Growing replacement organs. Approved cell therapies exist in narrow indications; no bioprinted solid organ has been implanted in a human with an established outcome, and reporting routinely uses the first to imply the second.
What it is
Repairing or replacing damaged tissue and organs — stem cell therapies, tissue engineering and organ regeneration.
What it does
It would shift medicine from managing degeneration to reversing it, which is what separates lifespan extension from healthspan extension.
Common misconception
That the field is close to organ replacement. Approved therapies exist in narrow indications; complex organ regeneration remains early, and the gap between those two facts is where most overclaiming happens.
Steepens
- Longevity and the Healthspan Gap — large
- The Care Economy — moderate
- The Silver Economy — moderate
What would change its gradient
- Manufacturing at cost — cell therapies are made per patient, which is a scale problem
- Vascularisation, the central technical barrier to complex tissue
- Reimbursement pathways for one-time high-cost interventions
Shares megatrends with
- Assistive & Care Technology
- Longevity & Healthspan Interventions
- Brain-Computer Interfaces
- Family Formation
- BioTech & Genomics
- Gene Editing
In the book
Why the Future Arrives Unevenly — Ch. 7 — The Inversion of the Population Pyramid · Ch. 12 — Reading the Ramp · Ch. 14 — How Hype Is Manufactured
Sources
- Approved products exist and are deployed for narrow indications; commercial viability, not science, is the binding constraint, and complex organ regeneration remains preclinical. Source: EMA CAT quarterly highlights (EMA/147429/2026): 31 ATMPs authorised Dec 2008–Dec 2025, 7 withdrawn and 2 expired. Peer-reviewed: Int. J. Technology Assessment in Health Care (2024) — 22% of EMA-authorised ATMPs withdrawn, six of seven for COMMERCIAL reasons, not safety or efficacy. FDA lists 40+ approved cell and gene therapy products. ⚠ No bioprinted or lab-grown SOLID organ has been implanted in a human with an established outcome (2008–2026).